Skip to main content

Table 3 Hearing loss (dB) 3 months post first fitting compared to baseline: results of the primary analysis ANCOVA model in the ITT set

From: Randomized placebo-controlled clinical trial investigating the effect of antioxidants and a vasodilator on overall safety and residual hearing preservation in cochlear implant patients

 

Estimate

Standard error

p value

95% confidence interval

ACEMg - placebo

− 4.15

4.3641140

0.3468

(− 12.95, 4.65)

Surgeon 2 - other surgeons

− 2.03

4.7141858

0.6688

(− 11.54, 7.48)

Flex 24 - Flex 20

35.32

9.9561928

0.0010

(15.24, 55.40)

Flex 28 - Flex 20

42.14

12.2218146

0.0013

(17.49, 66.79)

Flex 28 - Flex 24

6.82

6.8177036

0.3231

(− 6.93, 20.56)

Baseline hearing at 500 Hz (dB)

− 0.48

0.1849977

0.0136

(− 0.85, − 0.10)